Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AdoRx Therapeutics

Request full access

Adenosine pathway modulators for cancer immunotherapy

Edinburgh, United KingdomFounded 2017Biotech & Life Sciences

About AdoRx Therapeutics

AdoRx Therapeutics is a UK-based drug discovery company established in 2017, focusing on the development of new cancer therapeutics. The company’s core strategy is to modulate the adenosine pathway to counteract cancer's ability to evade the immune system. High concentrations of adenosine in the tumor microenvironment suppress immune responses; AdoRx aims to overcome this by designing and developing fit-for-purpose adenosine receptor antagonists.

AdoRx was founded by healthcare investor Epidarex Capital and is led by a team of veterans from the pharmaceutical industry. The leadership team, including CEO Pete Finan, former head of the Novartis Institutes of BioMedical Research UK site, Dr. Clive McCarthy, and Dr. Roy Pettipher, collectively holds extensive experience, having advanced over twenty-five drug candidates into clinical development. The company operates on a research and development model, financed through venture capital and strategic partnerships. In June 2018, AdoRx announced an initial funding round of $10 million from investors Epidarex Capital and the CRT Pioneer Fund.

A significant milestone was achieved in February 2019, when AdoRx entered a strategic collaboration with Johnson & Johnson Innovation and its Lung Cancer Initiative. This partnership granted an exclusive option to research, develop, and commercialize novel antagonists from AdoRx's portfolio for lung cancer treatment. The company's product pipeline is in the pre-clinical stage and includes antagonists for the Adenosine A2A receptor and dual-blockade antagonists for A2A/A2B receptors.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
26.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2018 $10M $40M Epidarex Capital · Sixth Element Capital · Oxford University Innovation ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

AdoRx Therapeutics website traffic

Latest recorded traffic for AdoRx Therapeutics is 100 monthly website visits, down 84.4% over the last three months. AdoRx Therapeutics's team grew 0% over the past year.

Latest monthly visits100 3-month web change-84.4% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AdoRx Therapeutics in the Edinburgh ecosystem

Live from Dealroom

The AdoRx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Epidarex Capital
  • Sixth Element Capital
  • Oxford University Innovation
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · Edinburgh HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AdoRx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AdoRx Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.